iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) is Blume Capital Management Inc.’s 10th Largest Position

Blume Capital Management Inc. grew its holdings in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 9.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,939 shares of the financial services provider’s stock after buying an additional 4,793 shares during the quarter. iShares Nasdaq Biotechnology ETF accounts for about 3.2% of Blume Capital Management Inc.’s investment portfolio, making the stock its 10th largest holding. Blume Capital Management Inc. owned about 0.08% of iShares Nasdaq Biotechnology ETF worth $8,827,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in IBB. Investment Management of Virginia LLC acquired a new stake in iShares Nasdaq Biotechnology ETF in the second quarter worth $573,000. Mercer Global Advisors Inc. ADV increased its holdings in shares of iShares Nasdaq Biotechnology ETF by 34.9% during the second quarter. Mercer Global Advisors Inc. ADV now owns 3,799 shares of the financial services provider’s stock valued at $622,000 after purchasing an additional 982 shares during the period. Avantax Planning Partners Inc. increased its holdings in shares of iShares Nasdaq Biotechnology ETF by 5.0% during the second quarter. Avantax Planning Partners Inc. now owns 1,649 shares of the financial services provider’s stock valued at $270,000 after purchasing an additional 78 shares during the period. Edgestream Partners L.P. acquired a new position in shares of iShares Nasdaq Biotechnology ETF during the second quarter valued at $352,000. Finally, Van Leeuwen & Company LLC acquired a new position in iShares Nasdaq Biotechnology ETF during the second quarter worth about $256,000. Institutional investors own 71.40% of the company’s stock.

NASDAQ:IBB traded up $1.73 during mid-day trading on Wednesday, reaching $171.66. 27,357 shares of the stock were exchanged, compared to its average volume of 3,183,334. iShares Nasdaq Biotechnology ETF has a 1-year low of $128.23 and a 1-year high of $177.37. The business has a fifty day moving average price of $168.51 and a 200 day moving average price of $159.13.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.